Vicore Pharma Holding (NASDAQ:VCRE) Shares Shorted: Short Interest Up 941.7% in October

Vicore Pharma Holding (NASDAQ:VCRE) was the target of a significant growth in short interest in October. As of October 30th, there was short interest totaling 10,709 shares, a growth of 941.7% from the October 15th total of 1,028 shares. Based on an average daily volume of 22,655 shares, the days-to-cover ratio is currently 0.5 days.

Vicore Pharma Trading Down 0.4%

Shares of VCRE opened at $11.31 on Thursday. Vicore Pharma has a 1 year low of $7.88 and a 1 year high of $17.80.

Vicore Pharma (NASDAQ:VCRE) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.04) EPS for the quarter. The business had revenue of $0.06 million for the quarter.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on VCRE. Weiss Ratings started coverage on shares of Vicore Pharma in a report on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. Jefferies Financial Group assumed coverage on shares of Vicore Pharma in a report on Friday, October 9th. They set a “buy” rating and a $25.00 price objective for the company. Chardan Capital started coverage on shares of Vicore Pharma in a research report on Wednesday, November 4th. They issued a “buy” rating and a $15.00 target price for the company. Finally, Wall Street Zen raised Vicore Pharma to a “hold” rating in a research note on Saturday, October 24th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $20.00.

About Vicore Pharma

Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs. Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.